Functional antagonism of different angiotensin II type I receptor blockers in human arteries

Cardiovascular Drugs and Therapy

Volumn 16, Issue 4, 2002, Pages 311-316

  Wagenaar, Lodewijk J ^a   Voors, Adriaan A ^b   Buikema, Hendrik ^b   Van Buiten, Azuwerus ^b   Lübeck, Rob H ^a   Boonstra, Piet W ^a   Van Veldhuisen, Dirk J ^a   Van Gilst, Wiek H ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b University Hospital of Groningen ^*

Author keywords

Angiotensin II; Angiotensin receptor blockers; Arteries; Human; Vasoconstriction

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; PRIORITY JOURNAL; RECEPTOR BLOCKING; TISSUE GRAFT; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; LOSARTAN; MAMMARY ARTERIES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VASOCONSTRICTOR AGENTS;

EID: 12244290343     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021729909456     Document Type: Article

References (27)

1. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
2. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various ATI-receptor blockers in isolated vessels of different origin. Hypertension 1999;33:1406-1413.
3. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-217.
4. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Ther 1993;266:114-120.
5. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993;110:761-771.
6. Zhang J, Pfaffendorf M, Zhang JS, van Zwieten PA. A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations. Eur J Pharmacol 1994;252:337-340.
7. Baan J, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. J Hypertens 1998;16:1299-1305.
8. Cervenka L, Wang CT, Navar LG. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol 1998;274:F940-F945.
9. Garcha RS, Sever PS, Hughes AD. Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol 1999;127:1876-1882.
10. Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein. J Cardiovasc Pharmacol 1999;34:734-740.
11. Holmgren A, Pantev E, Erlinge D, Edvinsson L. Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries. J Cardiovasc Pharmacol 1998;32:662-664.
12. Buikema H, Grandjean JG, van der Broek SAJ, van Gilst WH, Lie KI, Wesseling H. Differences in vasomotor control between human gastroepiploic and left internal mammary artery. Circulation 1992;86:II205-II209.
13. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303-311.
14. McConnaughey MM, McConnaughey JS, Ingenito AJ. Practical considerations of the pharmacology of angiotensin receptor blockers. J Clin Pharmacol 1999;39:547-559.
15. Vauquelin G, Fierens FL, Verheijen I, Vanderheyden PM. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. J RAAS 2001;2:S24-S31.
16. Fierens FL, Vanderheyden PM, de Backer JP, Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: The role of tight antagonist binding. Eur J Pharmacol 1999;372:199-206.
17. Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46:311-318.
18. Fierens FL, Vanderheyden PM, de Backer JP, Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-tranfected Chinese hamster ovary cells. Eur J Pharmacol 1999;367:413-422.
19. Ojima M, Inada Y, Shibouta Y, et al. Candesartan (CV- 11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997;319:137-146.
20. Panek RL, Lu GH, Overhiser RW, Major TC, Hodges JC, Taylor DG. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 1995;273:753-761.
21. Rhaleb NE, Rouissi N, Nantel F, D'Orleans-Juste P, Regoli D. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension 1991;17:480-484.
22. Corriu C, Bernard S, Schott C, Stoclet JC. Effects of losartan on contractile responses of conductance and resistance arteries from rats. J Cardiovasc Pharmacol 1995;25:688-692.
23. Wong PC, Hart SD, Zaspel AM, et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990;255:584-592.
24. Baan J, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers. Cardiovasc Res 1996;32:973-979.
25. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000;13:18S-24S.
26. McClellan KJ,Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998;56:847-869.
27. Robertson MJ, Dougall IG, Harper D, McKechnie KC, Leff P. Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model. Trends Pharmacol Sci 1994;15:364-369.